comprehensive -WSS

comprehensive

author：comprehensive 2025-09-06 06:16:49 - browse：1

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Pregnancy discrimination could be enabled by AI

hotspot

WSS

National panel will explore requiring free Covid tests

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Scientists inch closer to single

CMS should re

Leukemia patients are helped by Syndax's new type of therapy

Wikipedia

comprehensive

hotspot

Affirmative action in medical school literally saved lives

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

Medicare details structure of new drug price negotiation program

What PEPFAR has meant on the ground in Ukraine

Trump demands the U.S. pay no more for drugs than other countries … again

The woman behind the Dana Farber

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

‘Oppenheimer’ and the risks of AI in health care

Continuity nursing helped my family in our darkest PICU moments

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

focus

Sage hopes for a blockbuster in antidepressant now before FDA

EQRx, failed developer of low

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Adults seen as increasingly susceptible to measles

FDA approves world's first CRISPR

NIH launches clinical trials and new research office for long Covid

knowledge

hotspot

hotspot

explore